Seeking Alpha Publishes Article Featuring Advaxis, Inc. (ADXS)
Advaxis is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to fight off cancer and disease.
Earlier this week, Seeking Alpha published the following article featuring Advaxis: seekingalpha.com
The article titled “Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind” provides an overview of the pharmaceutical industry and its challenges. Strong competition from generic drug companies are pressuring Big Pharma to produce a new pipeline of drugs, either through research & development or acquisitions. Based on activity in the market as the pharmaceutical industry moves beyond the hollow specter of the patent cliff, there is a definite interest in buying up companies with promising efforts.
Jonathan Yates, author of the article, wrote, “Advaxis has more than 15 constructs in various stages of development that are not only distinct, but many are in strategic collaborations with such heavyweights as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institute, and others . . . Advaxis’ lead construct, ADXS-HPV, was honored as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards.”
While honors and awards light up a press release, investors only care about the glow from the bottom line. For the global market for immunotherapies from companies such as Advaxis and Dendreon, sales are estimated to be about $40 billion.
For more information, visit www.advaxis.com
Please see disclaimer on our profile |
